OBE001 Phase I PK study in pregnant women with indicated termination

• Research type

  Research Study

• Full title

  A phase I, open-label study to assess the pharmacokinetic profile, safety and tolerability of OBE001 after a single oral administration in pregnant women with medically indicated pregnancy termination.

• IRAS ID

  149069

• Contact name

  Phillip Bennett

• Contact email

  p.bennett@imperial.ac.uk

• Sponsor organisation

  ObsEva S.A.

• Eudract number

  2013-005048-27

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• REC name

  South Central - Berkshire Research Ethics Committee

• REC reference

  14/SC/0132

• Date of REC Opinion

  31 Mar 2014

• REC opinion

  Favourable Opinion